福瑞股份(300049) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥322,803,586.32, representing a 33.35% increase compared to ¥242,063,684.65 in the same period last year [19] - Net profit attributable to shareholders was ¥42,719,144.08, a significant increase of 228.57% from ¥13,001,623.68 in the previous year [19] - The net profit after deducting non-recurring gains and losses was ¥41,291,171.98, up 126.24% from ¥18,251,415.69 year-on-year [19] - Basic earnings per share rose to ¥0.1624, reflecting a 228.74% increase compared to ¥0.0494 in the same period last year [19] - The company achieved total operating revenue of 323 million RMB, a year-on-year increase of 33.35% [26] - Net profit attributable to shareholders reached 42.72 million RMB, up 228.57% compared to the same period last year [26] - The net profit excluding non-recurring gains and losses was 41.29 million RMB, reflecting a growth of 126.24% year-on-year [26] - The total comprehensive income for the period was CNY 48,359,540.62, compared to CNY 41,774,567.26 in the previous period, representing an increase of approximately 13.8% [44] - Basic and diluted earnings per share increased to CNY 0.1624 from CNY 0.0494, marking a significant growth of 228.4% [44] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,683,857,409.32, a 1.37% increase from ¥2,647,472,861.45 at the end of the previous year [19] - The company's total assets increased to ¥2,683,857,409.32 from ¥2,647,472,861.45, marking a growth of 1.4% [41] - Current liabilities totaled ¥301,255,455.54, slightly up from ¥298,367,511.93, indicating a marginal increase of 0.6% [41] - Non-current liabilities rose to ¥532,924,699.40 from ¥501,725,944.13, reflecting a 6.2% increase [41] - The total equity attributable to shareholders increased to ¥1,566,671,495.95 from ¥1,547,323,178.35, a growth of 1.3% [41] Cash Flow - Cash flow from operating activities decreased by 45.47% to ¥38,481,610.14 from ¥70,573,746.91 in the previous year [19] - The company's cash flow from operating activities showed significant improvement, contributing to the overall financial health [36] - Cash inflows from operating activities totaled CNY 326,178,886.99, slightly up from CNY 325,225,260.79, indicating stable operational performance [48] - Net cash flow from operating activities decreased to CNY 38,481,610.14 from CNY 70,573,746.91, reflecting a decline of approximately 45.4% [49] - Cash and cash equivalents at the end of the period were CNY 492,907,321.64, down from CNY 535,049,843.40, a decrease of approximately 7.9% [49] - The company received CNY 13,096,924.05 in cash from financing activities, a significant increase from CNY 422,532.12 in the previous period [49] - The net cash flow from financing activities improved to CNY 8,562,547.47 from CNY -2,714,178.14, indicating a positive shift in financing operations [49] Operational Highlights - The growth in performance is primarily attributed to the continuous expansion of the company's medical device business [26] - The company has adopted a management-oriented medical strategy focusing on "new pathways for high-risk liver cancer screening + new strategies for secondary prevention + value-based payment for traditional Chinese medicine" as its core direction [26] - The company is transitioning towards an academic project-oriented drug marketing model, significantly enhancing its performance in drug sales and managed medical services [26] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth [34] Taxation and Expenses - Tax payable increased by 43% to ¥54,300,887.42, attributed to higher revenue leading to increased value-added tax [22] - The company experienced a 120% increase in taxes and surcharges, amounting to ¥2,101,548.89, due to increased sales of pharmaceuticals and medical devices [22] - Operating costs for the first quarter were ¥234,675,665.98, up from ¥185,573,350.49, reflecting a 26.5% increase [41] - The company reported a decrease in accounts payable from ¥80,093,496.70 to ¥71,318,092.45, a reduction of 10.5% [41]